SARS-COV-2 IgG antibody response in pregnant women at delivery.
Adult
Antibodies, Viral
/ blood
Antibody Formation
/ immunology
COVID-19
/ epidemiology
Female
France
/ epidemiology
Gestational Age
Humans
Immunoglobulin G
/ blood
Infant, Newborn
Paris
/ epidemiology
Parturition
Pregnancy
Pregnancy Complications, Infectious
/ epidemiology
Pregnancy Outcome
Prospective Studies
SARS-CoV-2
/ immunology
Seroepidemiologic Studies
COVID-19
Pregnancy
SARS-CoV-2
Seroprevalence
Journal
Journal of gynecology obstetrics and human reproduction
ISSN: 2468-7847
Titre abrégé: J Gynecol Obstet Hum Reprod
Pays: France
ID NLM: 101701588
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
24
10
2020
revised:
04
12
2020
accepted:
07
12
2020
pubmed:
15
12
2020
medline:
26
8
2021
entrez:
14
12
2020
Statut:
ppublish
Résumé
The prevalence of COVID-19 infection during pregnancy is not known. COVIPREG is a prospective French multicenter study to assess the seroprevalence at the time of delivery and the maternal and neonatal impact of COVID-19 infection during pregnancy. In order to study factors associated with poor outcomes after COVID-19 Infection during pregnancy and adapt the sample size of the study, a preliminary assessment of the prevalence of SARS-CoV-2 IgG was planned after 500 inclusions in a one perinatal center of Paris area. To assess the prevalence of SARS-CoV-2 IgG antibody response in pregnant women at the time of delivery during the COVID-19 pandemia. A prospective observational study at Cochin hospital (Level III maternity). Patients admitted for delivery were offered to participate to the study. Each patient participating to the study was tested for anti-SARS-CoV-2-IgG antibodies using a commercially available ELISA. Among the 529 patients included in the COVIPREG study between April 29 and June 26, 529 were assessed for SARS-CoV-2 IgG antibody response and 25 had a positive test, ie 4.7 % with a confidence interval at 95 % [3.0 %-6.9 %]). Four months after the beginning of the infection in Paris, the seroprevalence of SARS-CoV-2 IgG in pregnant women at the time of delivery is low. Studies evaluating the impact of COVID-19 infection during pregnancy should take this information in account in order to adapt the sample size.
Sections du résumé
BACKGROUND
BACKGROUND
The prevalence of COVID-19 infection during pregnancy is not known. COVIPREG is a prospective French multicenter study to assess the seroprevalence at the time of delivery and the maternal and neonatal impact of COVID-19 infection during pregnancy. In order to study factors associated with poor outcomes after COVID-19 Infection during pregnancy and adapt the sample size of the study, a preliminary assessment of the prevalence of SARS-CoV-2 IgG was planned after 500 inclusions in a one perinatal center of Paris area.
OBJECTIVES
OBJECTIVE
To assess the prevalence of SARS-CoV-2 IgG antibody response in pregnant women at the time of delivery during the COVID-19 pandemia.
STUDY DESIGN
METHODS
A prospective observational study at Cochin hospital (Level III maternity). Patients admitted for delivery were offered to participate to the study. Each patient participating to the study was tested for anti-SARS-CoV-2-IgG antibodies using a commercially available ELISA.
RESULTS
RESULTS
Among the 529 patients included in the COVIPREG study between April 29 and June 26, 529 were assessed for SARS-CoV-2 IgG antibody response and 25 had a positive test, ie 4.7 % with a confidence interval at 95 % [3.0 %-6.9 %]).
CONCLUSIONS
CONCLUSIONS
Four months after the beginning of the infection in Paris, the seroprevalence of SARS-CoV-2 IgG in pregnant women at the time of delivery is low. Studies evaluating the impact of COVID-19 infection during pregnancy should take this information in account in order to adapt the sample size.
Identifiants
pubmed: 33310133
pii: S2468-7847(20)30417-7
doi: 10.1016/j.jogoh.2020.102041
pmc: PMC7831450
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
102041Informations de copyright
Copyright © 2020 Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest CVF has obtained a grand from Ferring pharmaceutics for the COVIPREG study.
Références
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
Sci Immunol. 2020 Jul 29;5(49):
pubmed: 32727884
J Clin Invest. 2020 Oct 1;130(10):5235-5244
pubmed: 32634129
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Infect. 2020 Jul;81(1):147-178
pubmed: 32209385
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
Clin Infect Dis. 2020 Jul 28;71(15):778-785
pubmed: 32198501
N Engl J Med. 2020 Oct 29;383(18):1757-1766
pubmed: 32329974
Lancet. 2020 Aug 22;396(10250):530-531
pubmed: 32771084
J Med Virol. 2020 Jun;92(6):577-583
pubmed: 32162702
Obstet Gynecol. 2020 Jul;136(1):65-67
pubmed: 32332320
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32513859
Am J Obstet Gynecol. 2020 Jun;222(6):521-531
pubmed: 32217113
J Gynecol Obstet Hum Reprod. 2020 Sep;49(7):101826
pubmed: 32505805
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Lancet Infect Dis. 2020 Dec;20(12):1390-1400
pubmed: 32979318
Lancet Infect Dis. 2020 Sep;20(9):e245-e249
pubmed: 32687805
Nat Commun. 2020 Jul 14;11(1):3572
pubmed: 32665677
N Engl J Med. 2020 Dec 17;383(25):2451-2460
pubmed: 32412710